Biogen, Denali Announce Billion-Dollar Collaboration On Parkinson's Treatment [Investor's Business Daily]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Investors Business Daily
Related news Biogen and Denali Therapeutics early Thursday announced a collaboration to move forward on testing on a treatment for Parkinson's disease, sending DNLI stock soaring. Drug giant Biogen ( BIIB ) is committing more than $1 billion toward the effort. It will take an 11% stake in Denali Therapeutics ( DNLI ), buying 13.3 million shares at $34.94 per share. It also will make an upfront payment of $560 million. Also, Denali will be eligible to receive up to $1.125 billion in potential milestone payments based on meeting certain development and commercial milestones. On the news, DNLI stock shot up nearly 40%, around 32.50, in morning trades on the stock market today . That would mark an all-time high for DNLI stock, which touched its regular-session high of 30.41 on Jan. 31. DNLI stock, though, hit its all-time low of 12.39 on March 31. Shares of BIIB stock ticked up 0.9% to 278.62. BIIB stock has been trending just below its 50-day moving average since late May. Denali and Bio
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- BioHive Announces BioHive Live [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at UBS Group AG from $70.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesPR Newswire
- Gain Therapeutics gets new chief medical officer [Seeking Alpha]Seeking Alpha
- Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- DNLI's page on the SEC website